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Abstract: Chronic heart failure (HF) is a major cause of morbidity and mortality particularly 
in the elderly and a growing healthcare burden in Italy. The objective was to assess the cost-
effectiveness of candesartan cilexetil, an angiotensin II type 1 receptor blocker (ARB) for the 
treatment of HF. A pre-speciﬁ  ed economic evaluation was conducted on resource utilization 
(cardiovascular drug treatment, cardiovascular and non-cardiovascular hospital admission, 
cardiovascular procedures/operations) prospectively collected alongside the CHARM program, 
a series of parallel randomized clinical trials comparing candesartan with placebo (standard 
therapy) in patients with NYHA Class II-IV HF: CHARM-Alternative (LVEF  40% patients 
not receiving ACE inhibitors because of previous intolerance); CHARM-Added (LVEF  40% 
patients currently receiving ACE inhibitors); or CHARM-Preserved (LVEF  40% patients). 
The primary outcome for the component trials was the composite of cardiovascular death or 
worsening hospital admission for HF and of the overall program all-cause mortality. Adjunc-
tive treatment with candesartan in CHARM-Alternative and CHARM-Added led to clinical 
beneﬁ  ts and to either cost-savings or a small additional cost, depending on the trial. The less 
certain clinical beneﬁ  t in CHARM-Preserved was obtained at modest extra cost. The incremental 
cost-effectiveness ratios (ICERs) were estimated to range from €713 per life year gained for 
CHARM-Alternative to dominant for CHARM-Added and the pooled reduced LVEF trials.
Keywords: candesartan, heart failure, cost-effectiveness analysis, cost-consequence analysis, 
CHARM, Italy
Background
Chronic heart failure (HF) is a major cause of morbidity and mortality particularly 
in the elderly and a growing problem in most afﬂ  uent countries given the expansion 
of aging populations (McMurray et al 1998; Mazza et al 2005). In Italy, one of the 
countries in the world with the highest proportion of persons above 65 years of age 
(United Nations Statistical Ofﬁ  ce 1991), HF creates a signiﬁ  cant burden on healthcare 
budgets (SEOSI Investigators 1997). While advances in the management of HF in the 
past several decades have signiﬁ  cantly decreased the mortality and morbidity associ-
ated with this condition, hospitalization rates due to HF have remained on an upward 
trend (Koelling et al 2004; Jimenez-Navarro et al 2006). This may be due to a rise in 
both chronic HF incidence and survival.
Cost-effective HF disease management and prevention are programs of equal 
importance in the drive to successfully combat the burden of the widespread disease 
of HF in Italy. The aim must begin with the reduction of HF hospitalization and it can 
therefore be expected that re-hospitalization rates are factors that will be increasingly 
scrutinized in the selection of HF treatments by healthcare providers in justifying the 
cost of treatment. The current paper describes the cost-effectiveness of candesartan 
cilexetil for the treatment of HF in Italy.Vascular Health and Risk Management 2008:4(1) 224
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Results of the CHARM (Candesartan in Heart failure: 
Assessment of Reduction in Mortality and morbidity) pro-
gram (Swedberg et al 1999; Granger et al 2003; McMurray 
et al 2003a, b; Pfeffer et al 2003; Yusuf et al 2003; Young 
et al 2004) suggest that candesartan reduces morbidity and 
mortality in patientswith HF and LV ejection fraction (LVEF) 
 40%, as well as those with LVEF  40%. Thus, when admin-
istered as an alternative to an angiotensin-converting enzyme 
(ACE) inhibitor, or as an add-on to standard therapy including 
an ACE inhibitor and/or beta blockers, candesartan has been 
shown to provide cardiovascular beneﬁ  ts in symptomatic HF 
including the decrease in the risk of hospital admission for 
worsening HF and deaths due to cardiovascular causes in HF. 
These outcomes have been further translated into economic 
beneﬁ  ts based on the analysis of cost-consequence and cost-
effectiveness of the resource use data collected prospectively 
alongside the CHARM study (Reed et al 2005). The focus of 
the current paper is on the cost effectiveness of candesartan 
in HF from the perspective of the National Health Service 
(SSN Servizio Sanitario Nazionale) in Italy.
Methods
Study design
A pre-speciﬁ  ed economic evaluation was conducted on 
resource utilization collected alongside the CHARM pro-
gram. Methods employed in the current research complied 
with the published guidelines for the conduct of economic 
evaluations in Italy (Capri et al 2001). In addition, given 
the multinational scope of economic evaluations (including 
those previously published (McMurray et al 2006) conducted 
alongside the CHARM program, and the inherent meth-
odological challenges that exist for meeting the important 
objectives of generalizability, transparency, and statistical 
power, the research methods employed were also developed 
in respect to the consensus frameworks that are currently 
being developed in the literature to address these difﬁ  culties 
(Reed et al 2005).
Within the CHARM program itself, patients with NYHA 
Class II-IV HF recruited from 26 countries were enrolled 
into one of three trials: CHARM-Alternative (patients with 
LVEF 40% or less who were not receiving ACE inhibi-
tors because of previous intolerance) (Granger et al 2003); 
CHARM-Added (patients with LVEF 40% or less or who 
were currently receiving ACE inhibitors) (McMurray et al 
2003b); or CHARM-Preserved (patients with LVEF higher 
than 40%) (Yusuf et al 2003). Overall, 7601 patients (7599 
with data) were randomly assigned candesartan (n = 3803, 
titrated as tolerated to 32 mg once daily) or matching placebo 
(n = 3796), and followed up for at least 2 years. The primary 
outcome of the overall program was all-cause mortality and 
for the two reduced LVEF trials combined (CHARM Alter-
native and Added), and for each of the component trials was 
the composite of cardiovascular death or worsening hospital 
admission for HF.
Resource utilization data collection
Data on resource utilization were collected prospectively and 
only comprised components of direct costs including, cardio-
vascular drug treatment (eg, digitalis glycosides, diuretics, 
beta-blockers, calcium channel blockers, other vasodilators, 
anti-arrhythmic drugs, ACE inhibitors, angiotensin II type 1 
receptor blockers [ARBs], or other cardiovascular drugs such 
as lipid-lowering agents and anticoagulants), cardiovascular 
and non-cardiovascular hospital admission (eg, proportion of 
patients admitted, number of admissions per patient, number 
of hospital days per patient) and ward type for cardiovascu-
lar admission (eg, intensive/coronary care unit, cardiology, 
general internal medicine), admissions for cardiovascular 
reasons (eg, number, duration, ward type), and cardiovascular 
procedures/operations. For costing non-cardiovascular hos-
pital admissions, it was assumed that 10% of time was spent 
in intensive care and 90% on the general ward. Indirect costs 
(work productivity losses) were not considered. The time 
horizon over which the cost-consequence and incremental 
cost-effectiveness of candesartan were compared to placebo 
was equivalent to that observed during the period of the 
program (ie, no future projections were made).
Estimation of costs
Hospital admissions
For the estimation of costs, two approaches were employed 
(CIBIS-II Investigators and Health Economics Group 2001); 
these included the diagnosis-related group (DRG) costing 
(with data obtained from Health Ministry, Tariffa Unica 
Nazionale TUC, 2006) and per diem (hospital bed-day) 
costing (with data obtained from (Azienda Ospedaliera di 
Busto Arsizio, Varese – Administration Dept in a group 
of Hospitals in Lombardy Region). In this analysis actual 
recorded days in hospital were multiplied by the daily unit 
costs of hospital care.
Drug treatment
The source for drugs costs was Gazzetta Ufﬁ  ciale n.227, 
29.09.2006; these were the standard tariffs for the ﬁ  nancial 
year 2006 and the costs of generic drugs were used where 
available. Candesartan treatment costs also accounted for Vascular Health and Risk Management 2008:4(1) 225
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the initiation and up-titration of candesartan, and included 
four extra GP visits and four checks of blood biochemistry 
(CIBIS-II Investigators and Health Economics Group).
Cardiovascular procedures
The DRG costs of cardiovascular procedures and opera-
tions were obtained from local government sources (Health 
Ministry, Tariffa Unica Nazionale TUC, 2006). Where there 
was a lapse in data given little reliable and comparable public 
information is available for the per diem costs of cardiovas-
cular procedures, DRG costs were used as proxies in the per 
diem analysis. All costs were converted to 2006 values using 
the local price index with the exception of drug prices which 
are for 2006. Costs are presented in the local currency (Euro) 
and were discounted at 3% for costs and outcomes (ISTAT 
2007; Capri et al 2001). The costs used in this analysis are 
summarized in Table 1.
Economic analysis
Effectiveness parameter employed
The effectiveness parameters employed in the analyses 
were as follows. For the component trials of the CHARM 
program the composite of cardiovascular death or hospital 
admission for worsening HF was employed. The candesartan 
to placebo hazard ratios for this outcome were as follows: 
CHARM-Alternative: 0.77 (95% CI 0.67–0.89, p = 0.0004) 
(Granger et al 2003); CHARM-Added: 0.85 (0.75–0.96, 
p = 0.011) (McMurray et al 2003b); CHARM-Preserved: 
0.89 (0.77–1.03, p = 0.118) (Yusuf et al 2003); the overall 
CHARM program: 0.84 (0.77–0.91, p   0.0001) (Pfeffer 
et al 2003). For the overall CHARM program and for the 
two reduced LVEF trials combined (CHARM-Alternative 
and Added) all-cause mortality was the pre-speciﬁ  ed primary 
endpoint (Swedberg et al 1999). The candesartan to placebo 
hazard ratio for this outcome in the overall CHARM program 
was 0.91 (0.83–1.00, p = 0.055) (Pfeffer et al 2003) and in 
the reduced LVEF trials 0.88 (0.79–0.98, p = 0.018) (Young 
et al 2004).
Economic analyses conducted
The economic analyses were based on the comparison of 
placebo, ie, standard therapy for HF to candesartan added 
to standard therapy. Two types of economic analyses were 
performed: these include a cost-consequence analysis (CCA) 
for a disaggregated examination of resource costs and health 
outcomes associated with the alternative interventions; and 
cost-effectiveness analysis (CEA) in which the alternative 
interventions are examined in light of total cost per unit 
of health outcome. Thus CCA was performed for each 
component trial and for the overall CHARM program using 
the primary outcome of the component trials as the measure 
of effectiveness. For this, the annual cost per patient treated to 
postpone or prevent one patient experiencing a cardiovascular 
death or hospital admission for worsening HF within the trial 
was calculated (Mauskopf et al 1998). For CEA, the incre-
mental cost-effectiveness ratios (ICERs), in terms of cost per 
life year gained (LYG), were estimated for the reduced LVEF 
trials given that there was a signiﬁ  cant increase in survival 
with candesartan in these two trials combined. CEA was not 
Table 1 Unit costsa used in the economic analysis of CHARM
Event  DRG cost in Italy
Hospitalizations
 Worsening  HF  2669.82
 Myocardial  infarction  3356.12
 Unstable  angina  1882.16
 Stroke
  Hemorrhagic  3391.02
  Ischemic/unknown/other  3391.02
  Transient ischemic attack  2124.34
 Cardiogenic  shock  2669.82
 Atrial  tachyarrhythmia  2213.55
 Ventricular  arrhythmia  5455.44
 Pulmonary  embolism  3710.82
  Other cardiovascular event  1765.16
 Cancer  (neoplasm)  2182.41
  Other non-cardiovascular event  939.69
Cardiovascular procedures
  Cardiac catheterizations including angiography  2722.25
 CABG  17898.67
  PTCA with stent  7878.69
  PTCA without stent  5455.44
  Implantation of cardioverter deﬁ  brillator  23876.00
  Implantation of pacemaker  9438.59
 Heart  transplantation  61066.70
  Ventricular assist device  7052.77
  Other cardiac surgery for HF  19419.16
  Other cardiovascular procedure/operation  9187.76
Per diem costs
  Intensive/coronary care unit  1860.65
 Cardiology  ward  600
  General medical ward  200
 Non-cardiovascular  admission  366.07
 Visit  general  practitioner  20.66
  Laboratory test – blood biochemistry  23.81
  Candesartan 4 mg  0.83
  Candesartan 8 mg  0.69
  Candesartan 16 mg  0.89
  Candesartan 32 mg  1.13
aAll costs shown in Euro (1€ = US$1.20 and £0.67).
Abbreviations: CABG, coronary artery bypass grafting; DRG, diagnosis related 
group; HF, heart failure; PTCA, percutaneous transluminal coronary intervention.Vascular Health and Risk Management 2008:4(1) 226
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performed for CHARM-Preserved given that no reduction 
was observed in that trial for candesartan in cardiovascular 
or all cause mortality.
Sensitivity analyses
Univariate sensitivity analyses were conducted by increasing 
the length of stay for non-cardiovascular admissions by 30% 
in the candesartan group to model the potential additional 
cost of possible adverse effects related to candesartan (White 
2003); adding an additional GP visit to account for a pos-
sible adverse event or laboratory abnormality; and testing the 
impact of alternative discount rates for costs and beneﬁ  ts in 
the range 0% and 8% (Capri et al 2001).
Statistical methods
Statistical analyses were performed using SAS software 
(version 8; SAS Institute Inc., Cary, NC, USA). The group 
mean approach was employed to account for censored data 
(eg, early dropouts and missing values) (Cook et al 2004) 
and bootstrapping, a technique which involves re-sampling 
was implemented as the test for signiﬁ  cance.
Results
Clinical outcomes
All-cause hospital admissions
The rates and number of hospital admissions in the overall 
CHARM program and each component trial (Table 2 and 
Figures 1 and 2) show that noteworthy differences between 
the placebo and treatment groups were obtained for the 
number of patients hospitalized in CHARM-Overall and 
CHARM-Alternative. In the CHARM-Overall trial 63.8% of 
patients in the placebo group were admitted to hospital at least 
once for any reason, compared with 62.4% in the candesartan 
group [odds ratio (OR) 0.94, 95% CI 0.86–1.03, p = 0.20]. 
In the CHARM-Alternative trial 63.3% of patients in the 
placebo group were admitted to hospital at least once for any 
reason, compared with 60.2% in the candesartan group (odds 
ratio [OR] 0.88, 95% CI 0.71–1.05, p = 0.15).
Additionally for CHARM-Overall, the number of 
admissions per patient hospitalized was 2.96 in the placebo 
group when compared with 2.82 in the candesartan group 
(p = 0.045). The average length of an individual admission 
was 8.9 days in the placebo group and 9.0 days in the cande-
sartan group. The average number of days spent in hospital 
for admitted patients was 26.3 days in the placebo group and 
25.2 days in the candesartan group. As a result, treatment 
with candesartan resulted in fewer hospital admissions (7182 
for placebo vs 6691 for candesartan or 1.060 compared with 
0.853 admissions per year of follow-up, p = 0.0001) and 
fewer days in hospital (placebo 63681, candesartan 59923; 
Table 2, p = ns). The number of days in hospital per patient-
year of follow-up was 6.0 in the placebo group and 5.5 in 
the candesartan group (p = 0.056).
Cardiovascular hospital admissions
The frequency of hospital admissions for speciﬁ  c cardiovas-
cular causes (Table 3 and Figure 2) shows that candesartan 
reduced both the proportion of patients admitted (−20%) and 
the number of admissions (−28%) for worsening HF. Atrial 
tachyarrhythmias also showed a trend toward reduction, while 
hospital admission for myocardial infarction showed a trend 
toward reduction in CHARM Added and CHARM Preserved. 
‘Other’ cardiovascular admissions were fewer in the candesar-
tan group in CHARM Alternative and CHARM-Added, and 
just nominally greater in the candesartan group in CHARM-
Preserved. Examination of these miscellaneous admissions did 
not reveal an excess in any speciﬁ  c category of event.
Procedures and operations
Other than cardiac catheterizations, the frequency of other 
cardiovascular procedures (Table 4), was relatively few and 
did not differ between treatment groups.
Economic outcomes
Costs of adjunctive candesartan treatment
The per diem cost analysis of adding candesartan to conven-
tional treatment (Table 5) shows that in CHARM-Overall the 
cost of care in the candesartan group was slightly (1%) less, 
even taking into account the cost of candesartan. There was a 
net cost-saving in both CHARM-Alternative and CHARM-
Added (5% reduction in cost in both trials). In CHARM-
Preserved, there was a net increase in the daily cost of care (6% 
increase in cost). The results of the DRG analysis (Table 6) 
were very similar; there was a small increase observed (2%) 
in the net daily cost of care with candesartan.
CCA
The CCA of the data (Table 7) shows that adjunctive treat-
ment with candesartan in CHARM-Alternative and CHARM-
Added led to clinical beneﬁ  ts and to either cost-savings or a 
small additional annual cost, depending on the trial. The less 
certain clinical beneﬁ  t in CHARM-Preserved was obtained 
at modest extra cost.
CEA
The CEA of the two reduced LVEF CHARM trials (Table 8) 
was conducted using a conservative approach of employing Vascular Health and Risk Management 2008:4(1) 227
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Table 2 Hospital admissions and patients hospitalized in CHARM
 CHARM-Alternative
 Placebo  (n  = 1015)  Candesartan (n = 1013)  Diff (95% CI)  p-value
All patients      
Patient-years 2582  2658   
No. deaths  296  265   
No. admissions  1835  1719   
No. hospl days  16,816  15,079   
Hosp days/adm  9.16  8.77  0.39 (−0.60, 1.38)  0.44
Adm/patient 1.81  1.70  0.11  (−0.10, 0.32)  0.30
Hosp days/patient  16.57  14.89  1.86 (−1.11, 4.47)  0.24
Hosp days/patient-year  6.51  5.67  0.84 (−0.27, 1.95)  0.13
Patients hospitalized      
No. hosp patient  643  610  0.88 (0.73, 1.05)  0.15
Adm/patient 2.85  2.82  0.04  (−0.25, 0.32)  0.80
Hosp days/patient  26.15  24.72  1.43(−2.73, 5.60)  0.50
 CHARM-Added
 Placebo  (n  = 1272)  Candesartan (n = 1276)  Diff (95% CI)  p-value
All patients      
Patient-years 3721  3846   
No. deaths  412  377   
No. admissions  2799  2462   
No. hospl days  24,161  21,902   
Hosp days/adm  8.63  8.90  −0.26 (−0.95, 0.43)  0.45
Adm/patient 2.20  1.93  0.27  (0.07,  0.47)  0.008
Hosp days/patient  18.99  17.16  1.83 (−0.65, 4.31)  0.15
Hosp days/patient-year  6.49  5.7  0.79 (−0.06, 1.64)  0.070
Patients hospitalized      
No. hospit patient  858  852  0.97 (0.82, 1.14)  0.71
Adm/patient 3.26  2.89  0.37  (0.13,  0.62)  0.003
Hosp days/patient  28.16  25.71  2.45 (−0.94, 5.85)  0.16
 CHARM-Preserved
 Placebo  (n  = 1509)  Candesartan (n = 1514)  Diff (95% CI)  p-value
All patients      
Patient-years 4387  4434   
No. deaths  244  237   
No. admissions  2548  2510   
No. hosp days  22,705  22,942   
Hosp days/adm  8.91  9.14  −0.23 (−1.02, 0.56)  0.57
Adm/patient 1.69  1.66  0.03  (−0.13, 0.20)  0.71
Hosp days/patient  15.05  15.15  −0.11 (−2.20, 2.01)  0.92
Hosp days/patient-year  5.18  5.17  0.01 (−0.73,0.75) 0.98
Hospitalized patients      
No. hosp patient  922  9.12  0.96 (0.83, 1.12)  0.63
Adm/patient 2.76  2.75  0.01  (−0.21, 0.23)  0.92
Hosp days/patient  24.63  25.16  −0.53 (−3.71, 2.65)  0.74
 CHARM-Overall
 Placebo  (n  = 3796)  Candesartan (n = 3803)  Diff (95% CI)  p-value
All patients      
Patient-years 10,690  10,938   
No. deaths  945  886   
No. admissions  7182  6691   
No. hosp days  63,681  59,923   
Hosp days/adm  8.87  8.96  −0.09 (−0.55, 0.38)  0.71
Adm/patient 1.89  1.76  0.13  (0.02,  0.24)  0.018
Hosp days/patient  16.78  15.76  1.02 (−0.38, 2.42)  0.15
Hosp days/patient-year  5.96  5.48  0.48 (−0.02,0.98) 0.056
(Continued)Vascular Health and Risk Management 2008:4(1) 228
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DRG costs only as all scenarios with per diem costs obtained 
results of cost-savings. Thus, following this approach in terms 
of the cost per LYG, the incremental cost-effectiveness ratio 
(ICER) was estimated to range from €713 for CHARM-
Alternative to dominant for CHARM-Added and the pooled 
reduced LVEF data. The results for Italy are consistent with 
the results in France, Germany, and the UK.
Sensitivity analyses
The sensitivity analyses (Table 9) showed that increasing 
the length of stay for non-cardiovascular admissions by 30% 
increased the cost per day in the candesartan group by 2%. 
As a result, candesartan was no longer cost-saving in any 
comparison. Adding one GP visit for an adverse event or 
laboratory abnormality which led to a reduction in the dose 
of, or discontinuation of candesartan resulted in an increase in 
daily costs by €0.01. As expected the cost per day is sensitive 
to changes in discount rate 0% and 8%.
Discussion
The CHARM program has shown that in treated patients, a 
substantial reduction in the proportion of patients admitted 
with worsening HF (and an even more marked reduction 
in the number of such admissions), without any increase 
in length of stay, contributed to a reduction in the rate of 
admission (and hospital bed days) for any reason, though this 
overall reduction was more modest. This is because the full 
impact of the reduction in admissions for worsening HF was 
Table 2 (Continued)
 CHARM-Overall
 Placebo  (n  = 3796)  Candesartan (n = 3803)  Diff (95% CI)  p-value
Hospitalized patients      
No.hospitalized patient  2423  2374  0.94 (0.86, 1.03)  0.20
Adm/patient 2.96  2.82  0.15  (0.003,  0.29)  0.045
Hosp days/patient  26.28  25.24  1.04 (−0.99, 3.07)  0.31
Figure 1 Cumulative number of hospital admissions.
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attenuated by increased survival in the candesartan-treated 
patients (who, therefore, spent more time at risk of hospital 
admission for other reasons).
Via economic analysis, it has been shown that the 
cost-savings accruing from even this modest reduction in 
the rate of hospital admission for any cause largely offset 
the cost of candesartan in Italy. According to the method 
of analysis (per diem compared with DRG), candesartan 
was, essentially, cost-neutral in the overall-CHARM pro-
gram (though clinical effectiveness was not proven in one 
component trial, CHARM Preserved). There was, how-
ever, heterogeneity between the component trials in the 
program. Although candesartan treatment was associated 
with either a small reduction or increase in the net overall 
cost of care in CHARM-Alternative and CHARM-Added, 
depending on the analysis, in CHARM-Preserved (in which 
candesartan treatment did not reduce the primary endpoint 
signiﬁ  cantly) there was a consistent and modest increase 
in the net cost of care. There appear to be two reasons for 
this. Though the proportional reduction in the rate and 
number of admissions for worsening HF was similar in all 
three CHARM trials, the absolute number of admissions 
prevented was smaller, relative to the number of patients 
treated, in CHARM-Preserved (ie, the rate of admission for 
worsening HF was lower in CHARM-Preserved, Figure 2). 
Consequently, the cost-offset was less in CHARM-Preserved 
than in the other two trials.
Another possible explanation is the increased number of 
‘other’ cardiovascular admissions in the candesartan group 
in CHARM-Preserved (a reduction, rather than excess, of 
these admissions was observed in the other CHARM trials), 
also observed with cardiovascular procedures in CHARM-
Preserved. As no speciﬁ  c pattern could be observed for the 
excesses in these outcomes, both increases may be viewed 
as a chance ﬁ  nding. Also noteworthy is the overall net cost 
of treatment in CHARM-Added (candesartan added to 
full conventional treatment, including an ACE-inhibitor), 
which was comparable to the net treatment cost obtained for 
CHARM-Alternative; and that the essentially cost-neutral 
outcome of these analyses of CHARM was obtained despite 
adding the cost of extra clinic visits and biochemical tests 
to reﬂ  ect the extra costs related to initiating, up-titrating the 
dose, and monitoring the effects of candesartan.
Our findings on the cost – consequences and cost-
effectiveness of using candesartan in Italy are consistent 
with the results observed in the economic evaluations 
Figure 2 Rates of hospital admission for any cause, all cardiovascular (CV) reasons, heart failure (HF) only, and non-cardiovascular reasons (p-values within brackets).
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of using candesartan in France, Germany, and the UK 
(McMurray et al 2006). In CE, the ICER was second only 
to the result obtained for France where candesartan was 
dominant across both of the reduced LVEF trials as well as 
their pooled data. Furthermore, although broadly in keep-
ing with economic analyses of other effective treatments 
for HF (Paul et al 1994; Glick et al 1995, 2002; CIBIS-II 
Investigators and Health Economics Group 2001), it is 
difﬁ  cult to directly compare the current and previously 
published candesartan studies to those. No other placebo-
controlled study included such a broad spectrum of patients, 
had within-trial data for such a long period of follow-up 
(with the exception of the ACE inhibitor enalapril in the 
treatment arm of the studies of LV dysfunction in the case 
of the latter) (Cook et al 2004), or added the drug to such 
extensive background treatment. Nevertheless, a consistent 
message from these prior economic analyses and ours is 
that reduction in hospital admission offsets the cost of 
treatment. Remarkably, the cost-offset has been sufﬁ  cient 
with all treatments examined, to date, to be cost-saving or 
more or less cost-neutral. This is despite each new drug 
being used as an additional treatment and against a trend 
of falling lengths of hospital stay.
The economic results, coupled with the clinical ﬁ  ndings 
of the CHARM program, have clear implications for the 
management of patients with HF in Italy. Not only does 
candesartan improve important clinical outcomes in HF but 
also offers these beneﬁ  ts at little or no additional cost to the 
health care system; indeed, its use in patients with HF and 
reduced LV systolic function may lead to an actual reduc-
tion in the direct costs of health care. This is an important 
ﬁ  nding for health-care providers and society more generally, 
because there is no trade-off between the interest of the 
individual patient and the greater population served by the 
health-care system.
As with any analysis of this type there were limitations. 
By using the full unit cost of candesartan, our analyses have 
reduced the cost-effectiveness of this treatment for the patient 
or private insurer who provides a co-payment for the cost 
of treatment (although this co-payment is exempt for the 
elderly in Italy). We did not take account of indirect costs, 
pension payments in those who survived were not taken 
account, costs related to death out of hospital. We had less 
detailed and complete information on non-cardiovascular 
procedures and drugs. However, the main driver of costs is 
hospital admission and we did have information on these 
and tried to account for lack of information on the former in 
our sensitivity analyses.
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Table 5 Daily per patient cost (€) of treatment in CHARM – per diem analysis
 CHARM-Alternative  CHARM-Added  CHARM-Preserved  CHARM-Overall
 Placebo  Candesartan  Placebo  Candesartan  Placebo   Candesartan Placebo  Candesartan
Hospitalizations  9.33  7.99  8.92 7.71  6.95 6.71  8.21 7.37
Cardiovascular  4.15  3.77  4.76 4.43  2.98 3.04  3.88 3.71 
procedures 
Concomitant  2.03  1.97  2.62 2.48  1.99 1.87  2.22 2.11 
medication
Study  drug  0.00  0.80  0.00 0.79  0.00 0.83  0.00 0.81
Titration  cost  0.00  0.18  0.00 0.16  0.00 0.16  0.00 0.17
Total 15.51  (0.85)a  14.71 (0.78)  16.30 (0.66)  15.56 (0.61)  11.93 (0.44)  12.61 (0.46)  14.31 (0.36)  14.16 (0.33)
astandard error within parentheses.
Table 6 Daily per patient cost of treatment (€) in CHARM – DRG analysis
 CHARM-Alternative  CHARM-Added  CHARM-Preserved  CHARM-Overall
 Placebo  Candesartan  Placebo  Candesartan  Placebo   Candesartan Placebo  Candesartan
Hospitalizations  3.85  3.37 3.88  3.18 2.80  2.55 3.43  2.97
Cardiovascular    4.15  3.77 4.76  4.43 2.98  3.04 3.88  3.71
procedures 
Concomitant    2.03  1.97 2.62  2.48 1.99  1.87 2.22  2.11
medication 
Study  drug  0.00  0.80 0.00  0.79 0.00  0.83 0.00  0.81
Titration  cost  0.00  0.18 0.00  0.16 0.00  0.16 0.00  0.17
Total 10.03  (0.50)a  10.09 (0.44)  11.26 (0.44)  11.04 (0.39)  7.77 (0.25)  8.45 (0.25)  9.53 (0.23)  9.76 (0.20)
astandard error within parentheses.
Table 7 Cost-consequence analysis of candesartan compared with placebo in the treatment of HF – clinical beneﬁ  ts and annual per 
patient saving/cost increase (95% CI)
Trial Clinical  beneﬁ  ts vs placebo  DRG costs  Per-diem costs
CHARM-Alternative  CV deaths (−15%) HF admission (−32%)  Net increase (€22 ± 245/year) Savings  (€291  ± 421/year)
CHARM-Added  CV deaths (−16%) HF admission (−17%) Savings  (€81  ± 214/year)   Savings (€267 ± 328/year)
CHARM-Preserved CV  deaths  (−1%), ns HF admission (−15%)  Net increase (€249 ± 128/year)  Net increase (€249 ± 232/year)
CHARM-Overall  CV deaths (−12%) HF admission (−21%)  Net increase (€83 ± 111/year) Savings  (€56  ± 179/year)
Abbreviations: CV, cardiovascular; DRG, diagnosis related group; HF, heart failure.
Table 8 Cost-effectiveness of candesartan in the CHARM reduced LVEF trials (based on DRG costs)
CHARM TRIAL LYG (95% CI)  Cost per LYG (95% CI)
   Italy  France  Germany  UK
Alternative  0.078 (0.003–0.15)  €713 (−7736; 431,600)  Dominant  €3881 (−17,728; 1,105,920)  €2547 (−18 171; 1 059 150)
Added 0.061  (−0.002–0.12) Dominanta  Dominant  €1427 (−14,479; –984,755)  Dominant
Reduced LVEF   0.068 (0.02–0.12)  Dominant  Dominant  €2997 (−19,183; 121,500)  €1348 (−16 225; 106 600)
pooled 
aDominant means a cost per LYG could not be calculated because costs were lower in the candesartan than in the placebo group.
Abbreviations: CV, cardiovascular; DRG, diagnosis related group; HF, heart failure; LVEF, left ventricular ejection fraction; LYG, life year gained.Vascular Health and Risk Management 2008:4(1) 233
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As with all economic analyses based on clinical trials 
of limited duration, there is concern that costs may only 
be postponed and that there may be ‘catch-up’ over the 
whole life-time of a patient. We believe that this is unlikely, 
given the relatively long-duration of follow-up of CHARM 
(37.7 months) compared with the average life-expectancy of 
patients with HF. We carried out a cost–consequence analysis 
of CHARM-Preserved even though the pre-speciﬁ  ed primary 
outcome was not reduced signiﬁ  cantly.
In summary, when added to currently recommended 
treatment, candesartan reduces hospital admissions for 
worsening HF and increases survival in patients with HF 
(Granger et al 2003; McMurray et al 2003a, b; Pfeffer et al 
2003; Yusuf et al 2003), speciﬁ  cally in those with low LVEF 
(Pfeffer et al 2003; Young et al 2004) and does this at little 
or no extra direct cost to the Italian health-care system. 
Candesartan is, therefore, a clinically and economically 
attractive adjunctive treatment for HF in Italy, represent-
ing signiﬁ  cant value to the individual patient as well as to 
health-care providers.
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